Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.
Vorinostat Plus Bevacizumab Had Activity in Previously Treated RCC
Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.
Does Active Surveillance Benefit Patients With Metastatic RCC?
Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.
Computer-Aided Evaluation of Tumor Response Could Benefit RCC Patients
Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.
Active Surveillance in Small Renal Masses
In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.
Pathology Aids in Diagnosis of Hereditary Leiomyomatosis, RCC
Suspicious pathology from kidney tumors was significantly associated with testing positive for fumarate hydratase mutations, which may aid in the early diagnosis of hereditary leiomyomatosis and renal cell carcinoma.
Long-Term RCC Control With Immunotherapy, Despite Early Discontinuation
Immunotherapy offers durable responses lasting more than 6 months after treatment discontinuation for some patients with metastatic renal cell carcinoma.
Kidney Cancer Highlights of 2016
This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.